Interpreting Hematology Smears

1. Indication for smear review — Automated flag (blast, left shift, nRBC, large unstained cells), physician request, abnormal CBC, or screening? Default: automated analyzer flag.
2. CBC data — Current CBC with automated differential, reticulocyte count, RBC indices (MCV, MCH, MCHC, RDW)? Default: available.
3. Clinical context — Suspected diagnosis, symptoms (fatigue, bleeding, fever, jaundice), medications, recent surgery/transfusion? Default: not provided; flag [VERIFY].
4. Prior smear reviews — Are there previous smear reports for comparison? Default: none on file.
5. Smear quality — Was the smear prepared from EDTA blood within 2 hours of collection? Default: yes.
6. Stain used — Wright, Wright-Giemsa, or May-Grunwald-Giemsa? Default: Wright-Giemsa.
7. Special stains — Are iron stain, reticulocyte stain, or malarial parasite examination needed? Default: no.

Documents to Request

• Current CBC with automated differential and histogram/scattergram
• Reticulocyte count and reticulocyte hemoglobin content (CHr/Ret-He)
• RBC indices (MCV, MCH, MCHC, RDW)
• Prior CBC and smear reports
• Clinical notes (symptoms, medications, transfusion history)
• Iron studies, B12, folate, LDH, haptoglobin, bilirubin (if hemolysis workup)
• Flow cytometry results (if concurrent)
• Bone marrow biopsy report (if available)

Step 1: Smear Quality Assessment

Evaluate the smear in the monolayer (counting) zone before interpreting morphology:

• Monolayer identification: The area where RBCs are evenly distributed, barely touching, and not overlapping. Located approximately 1/3 from the feathered edge.
• Staining quality: Adequate Wright-Giemsa staining shows pink-orange RBCs, purple WBC nuclei, and pink-blue WBC cytoplasm. Over-staining or under-staining can mimic hypochromia or obscure granulation.
• EDTA artifact assessment: > 2-hour-old EDTA specimens may show neutrophil hypersegmentation, platelet swelling, and crenated RBCs. Flag if specimen age > 4 hours.
• Platelet satellitism: EDTA-dependent phenomenon; if noted, recommend recollection in citrate for accurate platelet count.

Step 2: Red Blood Cell Morphology

Systematically evaluate RBC morphology using standardized grading:

RBC Morphology Grading (ICSH/CAP Recommendations)

Critical Schistocyte Assessment

Per ICSH 2012 consensus: Schistocytes are fragments with two or more pointed extremities (helmet cells, triangle cells, crescent cells). Microspherocytes and keratocytes may coexist. A count of > 1% schistocytes is significant and should prompt evaluation for TMA (TTP, HUS, DIC).

Step 3: White Blood Cell Differential and Morphology

Perform a 200-cell manual differential (or 100-cell if WBC < 1.0 x 10^9/L):

WBC Differential Interpretation

Critical WBC Findings — Immediate Action Required

Step 4: Platelet Estimation and Morphology

• Platelet estimate: Count platelets in 10 oil-immersion fields in the monolayer; average x 20,000 = estimated platelet count. Compare to automated count. Discrepancy > 30% warrants investigation (clumping, satellitism, giant platelets).
• Platelet morphology: Normal size (2-4 um), large platelets (> 4 um), giant platelets (approaching RBC size), platelet clumps (pseudothrombocytopenia).
• Causes of large/giant platelets: ITP, MYH9-related disorders, Bernard-Soulier syndrome, myeloproliferative neoplasms.
• Platelet clumping: If present, recommend recollection in citrate tube for accurate count. EDTA-dependent pseudothrombocytopenia affects ~0.1% of patients.

Step 5: Report Construction and Clinical Correlation

Assemble the smear interpretation report:

1. CBC correlation: State agreement or discrepancy between automated and smear-based estimates.
2. RBC morphology: Grade each abnormality using standardized scale. Comment on predominant finding.
3. WBC differential: Report 200-cell manual differential with absolute counts. Flag critical findings.
4. Platelet estimate: Concordant or discordant with automated count. Comment on morphology.
5. Impression/Comment: Integrate morphologic findings with clinical context. Provide differential diagnosis.
6. Recommendations: Suggest additional testing (flow cytometry, bone marrow, hemolysis labs, iron studies).

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was the smear reviewed in the correct monolayer zone with adequate staining quality?
2. Are all RBC morphologic abnormalities graded using standardized terminology (1+/2+/3+)?
3. Was a 200-cell manual differential performed for the WBC assessment?
4. Were critical findings (blasts, schistocytes > 1%, Auer rods) communicated as critical values?
5. Is the smear interpretation correlated with the automated CBC and clinical context?

Quality Audit

• Smear quality assessed (monolayer zone, stain quality, specimen age)
• RBC morphology systematically evaluated and graded per ICSH/CAP standards
• Schistocyte percentage quantified when fragments are present
• 200-cell manual differential performed (or 100-cell if WBC < 1.0 x 10^9/L)
• Blast cells identified and reported with morphologic description
• Auer rods specifically sought and documented when blasts are present
• Neutrophil toxic changes graded (granulation, Dohle bodies, vacuolation)
• Platelet estimate performed and compared to automated count
• Platelet clumping assessed and citrate recollection recommended if present
• nRBC count reported per 100 WBCs with corrected WBC count
• Smear findings correlated with automated CBC indices
• Critical findings reported via critical value notification pathway
• Parasites specifically evaluated when clinically indicated (travel, fever)

Guidelines

• Always review the smear in the monolayer zone; evaluating morphology in thick or thin areas produces systematic errors in cell sizing and staining assessment
• Grade all RBC morphologic abnormalities using a standardized scale (1+/2+/3+); avoid vague terms like "few" or "some"
• Quantify schistocytes as a percentage when present; > 1% is clinically significant and should trigger evaluation for thrombotic microangiopathy (TTP/HUS, DIC)
• Report all blasts seen on peripheral smear as a critical value requiring immediate clinician notification, regardless of the percentage
• Auer rods are pathognomonic for acute myeloid leukemia; their identification on a peripheral smear should be reported urgently even in the absence of a formal blast count
• Correct the automated WBC count when nucleated RBCs are present: corrected WBC = reported WBC x [100 / (100 + nRBCs per 100 WBCs)]
• For EDTA-dependent platelet clumping (pseudothrombocytopenia), recommend recollection in a citrate tube and correct the count by multiplying by 1.1 (for 3.2% citrate dilution)
• Correlate smear findings with clinical context in every report; morphology without clinical integration provides limited diagnostic value